Literature DB >> 26309897

Therapeutic challenges in renal cell carcinoma.

Justin C Penticuff1, Natasha Kyprianou1.   

Abstract

Renal cell carcinoma (RCC) is a malignancy that in advanced disease, is highly resistant to systemic therapies. Elucidation of the angiogenesis pathways and their intrinsic signaling interactions with the genetic and metabolic disturbances within renal cell carcinoma variants has ushered in the era of "targeted therapies". Advanced surgical interventions and novel drugs targeting VEGF and mTOR, have improved patient survival and prolonged clinically stable-disease states. This review discusses the current understanding of diagnostic challenges and the mechanism-based clinical evidence on therapeutic management of advanced RCC.

Entities:  

Keywords:  Angiogenesis; imaging; renal cancer; survival signaling; targeted therapies

Year:  2015        PMID： 26309897      PMCID： PMC4539109     

Source DB:  PubMed          Journal:  Am J Clin Exp Urol        ISSN： 2330-1910


  64 in total

1.  An update on current management of advanced renal cell cancer, biomarkers, and future directions.

Authors:  Wanqing Iris Zhi; Jenny J Kim
Journal:  Ann Cancer Res       Date:  2014

Review 2.  Renal-cell carcinoma.

Authors:  Herbert T Cohen; Francis J McGovern
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Rising incidence of small renal masses: a need to reassess treatment effect.

Authors:  John M Hollingsworth; David C Miller; Stephanie Daignault; Brent K Hollenbeck
Journal:  J Natl Cancer Inst       Date:  2006-09-20       Impact factor: 13.506

Review 5.  International variations and trends in renal cell carcinoma incidence and mortality.

Authors:  Ariana Znaor; Joannie Lortet-Tieulent; Mathieu Laversanne; Ahmedin Jemal; Freddie Bray
Journal:  Eur Urol       Date:  2014-10-16       Impact factor: 20.096

6.  Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape.

Authors:  B Escudier; C Chevreau; C Lasset; J Y Douillard; A Ravaud; M Fabbro; A Caty; J F Rossi; P Viens; J P Bergerat; J Savary; S Négrier
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

7.  Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.

Authors:  M Krieg; R Haas; H Brauch; T Acker; I Flamme; K H Plate
Journal:  Oncogene       Date:  2000-11-16       Impact factor: 9.867

8.  Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis.

Authors:  A Takahashi; H Sasaki; S J Kim; K Tobisu; T Kakizoe; T Tsukamoto; Y Kumamoto; T Sugimura; M Terada
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations.

Authors:  Joshua I Warrick; Alex Tsodikov; Lakshmi P Kunju; Arul M Chinnaiyan; Ganesh S Palapattu; Todd M Morgan; Ajjai Alva; Scott Tomlins; Angela Wu; Jeffrey S Montgomery; Khaled S Hafez; J Stuart Wolf; Alon Z Weizer; Rohit Mehra
Journal:  Hum Pathol       Date:  2014-02-20       Impact factor: 3.466
View more
  12 in total

1.  Genetic alterations in Japanese extrahepatic biliary tract cancer.

Authors:  Rei Noguchi; Kiyoshi Yamaguchi; Tsuneo Ikenoue; Yumi Terakado; Yasunori Ohta; Naohide Yamashita; Osamu Kainuma; Sana Yokoi; Yoshiaki Maru; Hiroki Nagase; Yoichi Furukawa
Journal:  Oncol Lett       Date:  2017-05-22       Impact factor: 2.967

Review 2.  Renal Cancer in the Elderly.

Authors:  Tania González León; Maricela Morera Pérez
Journal:  Curr Urol Rep       Date:  2016-01       Impact factor: 3.092

3.  Neferine increases sensitivities to multiple anticancer drugs via downregulation of Bcl-2 expression in renal cancer cells.

Authors:  Eun-Ae Kim; Ji Hoon Jang; Eon-Gi Sung; In-Hwan Song; Joo-Young Kim; Ho-Yong Sohn; Tae-Jin Lee
Journal:  Genes Genomics       Date:  2022-01-16       Impact factor: 1.839

Review 4.  Renal Cell Carcinoma: A Complex Therapeutic Challenge in the Elderly.

Authors:  Mashood Iqbal
Journal:  Cureus       Date:  2022-06-26

5.  [Expression and significance of fibroblast growth factor receptor 2 in clear cell renal cell carcinoma].

Authors:  T Y Cai; Z P Zhu; C R Xu; X Ji; T D Lv; Z K Guo; J Lin
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-08-18

6.  Eupatilin induces human renal cancer cell apoptosis via ROS-mediated MAPK and PI3K/AKT signaling pathways.

Authors:  Wei-Feng Zhong; Xiao-Hong Wang; Bin Pan; Feng Li; Lu Kuang; Ze-Xuan Su
Journal:  Oncol Lett       Date:  2016-08-10       Impact factor: 2.967

7.  Spatial Distribution of Private Gene Mutations in Clear Cell Renal Cell Carcinoma.

Authors:  Ariane L Moore; Aashil A Batavia; Jack Kuipers; Jochen Singer; Elodie Burcklen; Peter Schraml; Christian Beisel; Holger Moch; Niko Beerenwinkel
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.575

8.  The therapeutic potential of HIF-2 antagonism in renal cell carcinoma.

Authors:  Olivier Cuvillier
Journal:  Transl Androl Urol       Date:  2017-02

9.  Expression and significance of B7-H3 and Tie-2 in the tumor vasculature of clear cell renal carcinoma.

Authors:  Xianyun Zhang; Jindong Ji; Guangbo Zhang; Chuntao Fang; Fujin Jiang; Song Ma; Jianquan Hou
Journal:  Onco Targets Ther       Date:  2017-11-13       Impact factor: 4.147

10.  Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial.

Authors:  Ulka Vaishampayan; Patrick Schöffski; Alain Ravaud; Christian Borel; Julio Peguero; Jorge Chaves; John C Morris; Nuria Kotecki; Martin Smakal; Dongli Zhou; Silke Guenther; Marcis Bajars; James L Gulley
Journal:  J Immunother Cancer       Date:  2019-10-24       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.